
SATISFYING THE WRITTEN DESCRIPTION REQUIREMENT FOR LIVING INVENTIONS

> BETHANY R. ROAHRIG, PH.D. Bethany@setterroche.com

SETTER ROCHE LLP

OVERVIEW



Reduction to practice – the biological deposit



Requirements for a gene versus a genome

History of relevant caselaw



Structure and function for patenting purposes

The unique challenges of trait and gene based claims \swarrow



WRITTEN DESCRIPTION REQUIREMENTS & GOALS

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same....

35 U.S.C. 112(a)



WRITTEN DESCRIPTION REQUIREMENTS & GOALS

Goals of adequate written description

- Clearly convey that an Applicant has invented that which is claimed
- Satisfy the obligation to disclose the technical knowledge upon which the patent is based
- To demonstrate that the patentee was in possession of the invention *as claimed*

What is Sufficient to Satisfy the Written Description Requirement?



Detailed drawings



Structural chemical formulas



Any description of sufficient, relevant, identifying characteristics



An actual reduction to practice (biological deposit)

REDUCTION TO PRACTICE – THE BIOLOGICAL DEPOSIT



- A biological deposit shows actual reduction to practice
 - But this is not a substitute for a written description of the claimed invention
 - Additional identifying characteristics are required




an extinct genus of plants






Claiming the plant line as a whole




A description of the line



Claiming a specific trait or gene








Self propagation maintains the invention; crossing with another plant could create a new line/invention

Self propagation may or may not maintain the invention; crossing with another plant can *transfer* the invention

The issue ultimately lies with separation due to a self-replicating invention/technology







Noelle v. Lederman


2004

"Newly characterized antigen test" – claim to an antibody by its binding affinity to that antigen Newly characterized antigen test


Functional characteristics when coupled with a known or disclosed correlation between function and structure

a claim to an antibody satisfies the "function-structure test" where the antigen to which it binds has been fully characterized, and methods for making the antibody are routine"

quoting the Written Description Guidelines, 66 Fed. Reg. at 1106, n. 49, stating Id.








Newly characterized antigen test


Functional characteristics when coupled with a known or disclosed correlation between function and structure

a claim to an antibody satisfies the "function-structure test" where the antigen to which it binds has been fully characterized, and methods for making the antibody are routine"

quoting the Written Description Guidelines, 66 Fed. Reg. at 1106, n. 49, stating Id.







Amgen Inc. Patent No. 8,829,165

Claim 1: An isolated monoclonal antibody, wherein, when bound to PCSK9, the monoclonal antibody binds to at least one of the following residues: S153, I154, P155, R194, D238, A239, 1369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO:3, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR.




FIG. 17

Amgen v. Sanofi (2017)

Further, the "newly characterized antigen" test flouts basic legal principles of the written description requirement. Section 112 requires a "written description of the invention." But this test allows patentees to claim antibodies by describing something that is not the invention, i.e., the antigen. The test thus contradicts the statutory "quid pro quo" of the patent system where "one describes an invention, and, if the law's other requirements are met, one obtains a patent."

Recent Clarification

..."adequate written description of a newly characterized antigen *alone* should not be considered adequate written description of a claimed antibody to that newly characterized antigen, even when preparation of such an antibody is routine and conventional."



⁹ UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450 www.uspto.gov

MEMORANDUM

DATE: February 22, 2018


TO: Patent Examining Corps FROM: Robert W. Bahr Deputy Commissioner for Patent Examination Policy

SUBJECT: Clarification of Written Description Guidance For Claims Drawn to Antibodies and Status of 2008 Training Materials

The purpose of this memorandum is to clarify the applicability of USPTO guidance regarding the written description requirement of 35 U.S.C. § 112(a), specifically concerning the written description requirement for claims drawn to antibodies.

I. Federal Circuit Clarification of the Law of Written Description As It Applies to Antibodies

Recently, the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) decided *Amgen v. Sanofi*, 872 F.3d 1367 (Fed. Cir. 2017), which concerned adequate written description for claims drawn to antibodies. These claims are usually handled in Technology Center 1600. The Federal Circuit explained in *Amgen* that when an antibody is claimed, 35 U.S.C. § 112(a) requires adequate written description of the antibody itself. *Amgen*, 872 F.3d at 1378-79. The *Amgen* court expressly stated that the so-called "newly characterized antigen" test, which had been based on an example in USPTO-issued training materials and was noted in dicta in several earlier Federal Circuit decisions, should not be used in determining whether there is adequate written description under 35 U.S.C. § 112(a) for a claim drawn to an antibody. Citing its








Protein Amino Acids X-ray crystallography, NMR Static Deoxyribonucleic Acid Nucleotides Structure is known* Dynamic and degenerate Binary code Degenerate Structure is the sequence*


Analogous Art?





Courtesy: National Human Genome Research Institute (*with edits*) <u>https://www.genome.gov/</u>












- Look to the literature first
- Establish chromosomal markers and map location





- Look to the literature first
- Establish chromosomal markers and map location
- Sequence
- But where's the gene?

gcttgaggttctgtgaatttgggtgttccaaacaccctcagccctgtgtacccatcgatct gattaagtattcaggggcgcggtagttacaagagcaaccaagggaaccatttgcgcg gttcatgtgtaagaacaacccgagcggactcaagtggcgactacctaggtgcgtgggt tgtacccatccaggctttggtcactggacgatgattctttgtctctgatgacccgtagcta ttgtagtgcttgataactcagcaacggaatagtcggtccttgaagaacgctgcgtcaag tccggctccacgacctgatactgcccaccacgcaatcccattagaaatctggtcaggtg aagccgtacttctagttgtggaggatgacccgtcccttcgattagatcagccccacactc gaaggaacggtagtgcgggatgcatgacgctgattggaattcagtgaccagctcagc ggcgcgtacctgcgccacacttgtaaatcctcggccgcttgattacagcctgtcgacgg ctaagtgtctattgagaccagttaactttacaacattcgaaaagggcggagagtagaa gctgtgagccgtgagtgcccctgttgggtagaaattcgaccaccgggtacgagttgag ggggactctggtaatgaccaggtgatatggcatgttgtcgggagcttcacggat




- Look to the literature first
- Establish chromosomal markers and map location
- Sequence
- But where's the gene?
- Found a gene... is it the right one?

gcttgaggttctgtgaatttgggtgttccaaacaccctcagccctgtgtacccatcgatctgattaagtattcaggggcgcggtagttacaagagcaaccaagggaaccatttgcgcg gttcatgtgtaagaacaacccgagcggactcaagtggcgactacctaggtgcgtgggt tgtacccatccaggctttggtcactggacgatgattctttgtctctgatgacccgtagcta ttgtagtgcttgataactcagcaacggaatagtcggtccttgaagaacgctgcgtcaag tccggctccacgacctgatactgcccaccacgcaatcccattagaaatctggtcaggtg aagccgtacttctagttgtggaggatgacccgtcccttcgattagatcagccccacactc gaaggaacggtagtgcgggatgcatgacgctgattggaattcagtgaccagctcagc ggcgcgtacctgcgccacacttgtaaatcctcggccgcttgattacagcctgtcgacgg ctaagtgtctattgagaccagttaactttacaacattcgaaaagggcggagagtagaa gctgtgagccgtgagtgcccctgttgggtagaaattcgaccaccgggtacgagttgag ggggactctggtaatgaccaggtgatatggcatgttgtcgggagcttcacggat



- Look to the literature first
- Establish chromosomal markers and map location
- Sequence
- But where's the gene?
- Found a gene... is it the right one?
- Found the right one... which one is the causative mutation?

gcttgaggttctgtgaatttgggtgttccaaacaccctcagccctgtgtacccatcgatct gattaagtattcaggggcgcggtagttacaagagcaaccaagggaaccatttgcgcg gttcatgtgtaagaacaacccgagcggactcaagtggcgactacctaggtgcgtgggt tgtacccatccaggctttggtcactggacgatgattctttgtctctgatgacccgtagcta ttgtagtgcttgataactcagcaacggaatagtcggtccttgaagaacgctgcgtcaag tccggctccacgacctgatactgcccaccacgcaatcccattagaaatctggtcaggtg aagccgtacttctagttgtggaggatgacccgtcccttcgattagatcagccccacactc gaaggaacggtagtgcgggatgcatgacgctgattggaattcagtg<mark>a</mark>ccagctcagc ggcgcgtacctgcgccacacttgtaaatcctcggccgcttgattacagcctgtcgacgg ctaagtgtctattgagaccagttaactttacaacattcgaaaaggg<mark>cg</mark>gagagtagaa gctgtgagccgtgagtgcccctgttgggtagaaattcgaccaccgggtacgagttgag ggggactctggtaatgaccaggtgatatggcatgttgtcgggagcttcacggat



Other ways of establishing possession of a claimed invention may include unique cleavage by particular enzymes, isoelectric points of fragments, detailed restriction enzyme maps, a comparison of enzymatic activities, or antibody crossreactivity. Lockwood, 107 F.3d at 1572, 41 USPQ2d at 1966

- Clearly convey that an Applicant has invented that which is claimed
- Satisfy the obligation to disclose the technical knowledge upon which the patent is based
- To demonstrate that the patentee was in possession of the invention *as claimed*

What Satisfies the Written Description Requirement?

"Compliance with the written description requirement is essentially a fact-based inquiry that will 'necessarily vary depending on the nature of the invention claimed.'" *Enzo Biochem, 323 F.3d at 963, 63 USPQ2d at 1612*.

THANK YOU!



BETHANY R. ROAHRIG, PH.D. Bethany@setterroche.com

SETTER ROCHE LLP